Get started
Structure Therapeutics, Inc. Sponsored ADRStructure Therapeutics, Inc. Sponsored ADRStructure Therapeutics, Inc. Sponsored ADR

Structure Therapeutics, Inc. Sponsored ADR

No trades
See on Supercharts
OverviewFinancialsNewsDocumentsIdeasDiscussionsTechnicalsForecastSeasonalsOptionsETFs

GPCR chart


Full chart

GPCR upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.65 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.13 USD
Net income (FY)
‪−122.59 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪56.51 M‬
Beta (1Y)
1.08

About Structure Therapeutics, Inc. Sponsored ADR


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Raymond C. Stevens
Website
structuretx.com
Headquarters
South San Francisco
Founded
2016
ISIN
US86366E1064
FIGI
BBG01CBVHLW1
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Check out other big names from the same industry as GPCR.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

GPCR news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs with GPCR exposure


IBB
iShares Biotechnology ETF
Weight
0.11%
Market value
‪6.75 M‬
USD
OZEM
Roundhill GLP-1 & Weight Loss ETF
Weight
4.53%
Market value
‪1.67 M‬
USD
FBCG
Fidelity Blue Chip Growth ETF
Weight
0.03%
Market value
‪1.39 M‬
USD
EWX
SPDR S&P Emerging Markets Small Cap ETF
Weight
0.15%
Market value
‪1.13 M‬
USD
LRNZ
TrueShares Technology, AI & Deep Learning ETF
Weight
2.91%
Market value
‪999.81 K‬
USD
BTEC
iShares NASDAQ US Biotechnology UCITS ETF
Weight
0.14%
Market value
‪929.73 K‬
USD
BTEE
iShares NASDAQ US Biotechnology UCITS ETF
Weight
0.14%
Market value
‪929.73 K‬
USD
FDG
American Century Focused Dynamic Growth ETF
Weight
0.28%
Market value
‪910.17 K‬
USD
SBIO
ALPS Medical Breakthroughs ETF
Weight
0.84%
Market value
‪810.30 K‬
USD
FFSM
Fidelity Fundamental Small-Mid Cap ETF
Weight
0.10%
Market value
‪745.83 K‬
USD
SBIO
Invesco NASDAQ Biotech UCITS ETF
Weight
0.15%
Market value
‪587.48 K‬
USD

Explore more ETFs